Neurological and Musculoskeletal Features of COVID-19: A Systematic Review and Meta-Analysis

Auwal Abdullahi 1,2,*, Sevim Acaroz Candan 3, Muhammad Aliyu Abba 4,4, Auwal Hassan Bello 5, Mansour Abdullah Alshehri 6,7, Egwuonwu Afamefuna Victor 8, Naima Aliyu Umar 9 and Burak Kundakci 10

1 Department of Physiotherapy, Bayero University, Kano, Nigeria, 2 Department of Physiotherapy and Rehabilitation Sciences, University of Antwerp, Antwerp, Belgium, 3 Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences, Ordu University, Ordu, Turkey, 4 Department of Physiotherapy, University of Ibadan, Ibadan, Nigeria, 5 Department of Medical Rehabilitation, University of Maiduguri, Maiduguri, Nigeria, 6 Physiotherapy Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Mecca, Saudi Arabia, 7 NHMRC Center of Clinical Research Excellence in Spinal Pain, Injury and Health, School of Health and Rehabilitation Sciences, University of Queensland, Brisbane, QLD, Australia, 8 Department of Medical Rehabilitation, Nnamdi Azikiwe University, Awka, Nigeria, 9 Muhammad Abdullahi Wase Teaching Hospital, Kano, Nigeria, 10 University of Nottingham, Academic Rheumatology, Nottingham, United Kingdom

Importance: Some of the symptoms of COVID-19 are fever, cough, and breathing difficulty. However, the mechanism of the disease, including some of the symptoms such as the neurological and musculoskeletal symptoms, is still poorly understood.

Objective: The aim of this review is to summarize the evidence on the neurological and musculoskeletal symptoms of the disease. This may help with early diagnosis, prevention of disease spread, and treatment planning.

Data Sources: MEDLINE, EMBASE, Web of Science, and Google Scholar (first 100 hits) were searched until April 17, 2020. The key search terms used were “coronavirus” and “signs and symptoms.” Only studies written in English were included.

Study Selection: The selection was performed by two independent reviewers using EndNote and Rayyan software. Any disagreement was resolved by consensus or by a third reviewer.

Data Extraction and Synthesis: PRISMA guidelines were followed for abstracting data and assessing the quality of the studies. These were carried out by two and three independent reviewers, respectively. Any disagreement was resolved by consensus or by a third reviewer. The data were analyzed using qualitative synthesis and pooled using a random-effect model. Main Outcome(s) and Measure(s): The outcomes in the study include country, study design, participant details (sex, age, sample size), and neurological and musculoskeletal features.

Result: Sixty studies \( n = 11,069 \) were included in the review, and 51 studies were used in the meta-analysis. The median or mean age ranged from 24 to 95 years. The prevalence of neurological and musculoskeletal manifestations was 35% for smell impairment (95% CI 0–94%; \( I^2 \) 99.63%), 33% for taste impairment (95% CI 0–91%; \( I^2 \) 99.58%), 19% for myalgia (95% CI 16–23; \( I^2 \) 95%), 12% for headache (95% CI 9–15; \( I^2 \) 93.12%), 10% for back pain (95% CI 1–23; \( I^2 \) 80.20%), 10% for dizziness (95% CI...
COVID-19 on the nervous and musculoskeletal systems (1–8). Consequently, symptoms of COVID-19 can be many and may also vary. So far, the most common notable early symptoms of the disease are believed to be cough, headache, and fever (3). However, recently, evidence is emerging on the effect of COVID-19 on the nervous and musculoskeletal systems (6–8).

The effects of COVID-19 on the nervous and musculoskeletal systems may manifest as anosmia, olfactory function impairment, myalgia, muscle weakness, and Guillain Barre Syndrome (6–9). However, there is still little evidence on these, as scientists are still struggling to understand the disease process, including the pathogenicity, virucal replication, and epidemiology (2, 7). Ironically, in some patients, some of these symptoms may precede the commonest symptoms of COVID-19 (10). In addition, symptoms such as myalgia, muscle weakness, and headache may render the patients unable to carry out activities of daily living (ADL) such as walking. In humans, the ability to carry out ADL is associated with good quality of life (11, 12). Furthermore, symptoms such as muscle weakness can result in complications such as muscle atrophy and contracture in the long term. Therefore, identifying the neurological and musculoskeletal features of the disease would be beneficial and can provide further information with which to understand the diagnosis of COVID-19 and how to manage patients. The aim of this review is to summarize the evidence on the neurological and musculoskeletal symptoms of COVID-19.

METHODS

Design and Protocol

This is a systematic review and proportional meta-analysis that was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (13). However, the protocol was not registered in any systematic review register because of the urgent need for literature on COVID-19 that can help curb the spread and impact of the disease.

Eligibility Criteria and Information Sources

The inclusion criteria for this review were as follows: all studies with any study design that reported the neurological and musculoskeletal features in patients with COVID-19, studies published on or prior to April 17, 2020, and studies written in English. However, articles in the form of reviews, anecdotal description, and speculative considerations and editorials were excluded. Studies reporting exclusively on cases in children were also excluded. This is because the majority of the children infected with COVID-19 do not show any symptoms, and even in those who show symptoms, the symptoms tend to be limited to only mild fever and cough (1–4). Consequently, excluding children can enable us to generalize the findings to the adult population with COVID-19.

Four electronic databases, namely MEDLINE, EMBASE, Web of Science, and Google Scholar (first 100 hits), were searched from their date of establishment to April 17, 2020. The lists of references in the included studies were also screened for any relevant papers. The key search terms used were “coronavirus”...
and “signs and symptoms,” modified in terms of the glossary of each database and combined using Boolean operators. The search was carried out by one of the reviewers (BK). Appendix 1 demonstrates the search strategy applied in MEDLINE.

Selection of Eligible Studies and Extraction of Data

EndNote and Rayyan were used to remove any duplicates and select eligible studies from the database findings and other sources (lists of references in included studies). Two independent reviewers (AA and SAC) who have experience in conducting systematic reviews selected the eligible studies using Rayyan software (15). Any disagreement between reviewers was resolved by consensus or by a third reviewer (BK).

A standardized form was used to extract the relevant data by three reviewers (AA, NUM, and MAA). The data extracted from each study were the study details (study title, first author, year, setting/country, study design), participant details (sex, age, overall sample size, number of patients in critical and non-critical conditions, comorbidities, diagnostic criteria used for the disease (COVID-19), and information about the treatments received), and neurological features, such as headache, dizziness, impaired consciousness, acute cerebrovascular disease, ataxia, seizure, taste impairment, smell impairment, vision impairment, neuropathic pain, and musculoskeletal features such as myalgia and back pain. In addition, the number of patients presenting with a particular symptom was also extracted.

Assessment of the Methodological Quality of the Included Studies

A modified McMaster Critical Review Form for quantitative studies was used to critically assess the methodological quality of the included studies (16). This form is a comprehensive quality tool and can be used to assess all types of quantitative studies. It consists of 17 items with four answer options for each item (yes, no, not addressed and not applicable) to assess seven main components, including study purpose, literature review, study design, sample size, outcomes, interventions, results, and conclusions. Each item receives a score of zero when the answer to a particular item is no or not addressed and a score of one when the answer to a particular item is yes. However, when an item is not applicable to a particular study design, no score is awarded; NA is used to designate this. The scores from the tool are classified as poor, fair, good, or excellent, representing 1/4 or less, ≤2/4, ≥2/4 but ≤3/4, and >3/4 to 4/4 of the total score, respectively. The level of evidence was also determined using the National Health and Medical Research Council's (NHMRC) evidence hierarchy (17). Two independent reviewers performed the quality assessment (ABH and AA). Any disagreements between the first and the second reviewers were resolved through discussion to reach consensus and/or by a third reviewer (NUA). See the McMaster Critical Review Form in Appendix 2.

Data Analysis

Qualitative and quantitative data (descriptive and proportional meta-analysis) analyses were performed. The descriptive analysis was performed and represented in the form of summary tables. The proportional meta-analysis was performed using StataSE 16 for the quantitative data if there were at least two studies that reported the proportion of the same clinical symptom. A random-effect model due to the heterogeneity and Freeman-Tukey double arc-sine transformation were used to stabilize the variance of specific prevalence rates to minimize the impact of studies with extremely small or extremely large prevalence estimates on overall estimates (18). The $I^2$ index was also calculated to assess the level of heterogeneity, which can be classified into four categories: might not be important (0–40%), may represent moderate heterogeneity (30–60%), may represent substantial heterogeneity (50–90%), and considerable heterogeneity (75–100%). Publication bias was assessed using a funnel plot and Egger’s test (19).

RESULTS

A total of 1,301 published articles were identified from the electronic databases ($n = 1,298$) and other sources ($n = 3$). After the removal of duplicate studies ($n = 396$), 905 studies were eligible for an initial screening based on titles and abstracts. Following the initial screening, 771 records were removed, and the full-texts of 134 articles were screened against the defined eligibility criteria. After the full-text screening, 60 articles (4, 9, 10, 20–76) met the inclusion criteria and were used for qualitative synthesis. For the quantitative synthesis, only 51 articles (4, 9, 20–29, 31, 32, 34–36, 38, 41–43, 45–70, 72, 73, 75, 76) were used. Figure 1 shows the PRISMA flowchart.

The total number of participants in the included studies was 11,069, of which 5,168 were male. The median or mean age of the participants ranges from 24 to 95 years. Based on the studies reporting the situations of the patients, there were 2,377 and 4,882 participants in critical and non-critical conditions, respectively. The most common neurological manifestation was headache (35 studies; 58.33%) (4, 23, 25–28, 30, 31, 34–36, 41–48, 50, 52, 53, 56–63, 67–70, 72), followed by dizziness (6 studies; 10%) (29, 34, 45, 53, 54, 56), impaired smell sensation (5 studies; 8.33%) (33, 34, 36, 43, 55), impaired taste sensation (4 studies; 6.67%) (34, 36, 43, 53), acute cerebrovascular disease (2 studies; 3.33%) (34, 57), ataxia (2 studies; 3.33%) (9, 34), seizure (2 studies; 3.33%) (30, 34), impaired consciousness (1 study; 1.6%) (30), and impaired vision (1 study; 1.6%) (34). However, one study (20) reported non-specified neurological symptoms. The most common musculoskeletal manifestation was myalgia (48 studies; 80%) (4, 20–23, 25–29, 31, 32, 36–38, 41–44, 46–71, 73, 75, 76), followed by back pain (4 studies; 6.67%) (25, 40, 62, 63), muscle weakness (1 study; 1.67%) (9), skeletal muscle injury (1 study; 1.67%) (34), arthralgia (1 study; 1.67%) (36), and facial muscle pain (1 study; 1.67%) (36).

In terms of the study design, four of the four studies were case series (22, 34, 56, 76), 10 studies (9, 10, 27, 30, 33, 39, 40, 44, 71, 74) were case reports, and 46 studies (4, 20–26, 28–30, 33, 39, 40, 44, 71, 74) were either cohort or cross-sectional studies. All the studies were published in 2020. The settings/countries of the included studies were as follows: five studies (40, 43, 74–76) were carried out in the United States, and one each was carried out in the United Kingdom (33), Spain (38), Italy (9), South Korea (63), France (39), and Japan (30); one study (36)
is a multicenter study carried out in Europe (Belgium, France, Italy, and Spain). The rest of the studies (4, 10, 20–29, 31–35, 37, 41–62, 64–68, 70–73) were carried out in China. In most of the studies, the Chinese national CDC recommended protocol, World Health Organization (WHO) interim guidance, and real-time polymerase chain reaction (RT-PCR) were used to confirm the diagnosis of the disease. There were many comorbidities in the included studies such as hypertension, diabetes, cardiac or cerebrovascular disease, malignancy, chronic kidney disease, pituitary adenoma, chronic obstructive pulmonary disease, chronic renal failure, and cancer. Others are pregnancy, hepatitis B infection, allergic rhinitis, immune-suppression, history of head trauma, and neurological disease. Table 1 shows the details and characteristics of the included studies.

The methodological quality of the included studies was variable. Fifty-eight studies (4, 9, 10, 20–29, 25–39, 41–76) have excellent methodological quality, one study (40) has good methodological quality, and one study (24) has fair methodological quality. In terms of the level of the evidence (based on NHMRC evidence hierarchy), one study is a level II study, three studies are level III-I studies, 35 studies are level III-2 studies, seven studies are level III-3 studies, and 14 studies are level IV studies. Table 2 shows the methodological quality and the level of evidence of the included studies.

The proportional meta-analyses revealed that the prevalence of common neurological and musculoskeletal manifestations was 35% for smell impairment (95% CI 0–94%; $I^2$ 99.63%), 33% for taste impairment (95% CI 0–91%; $I^2$ 99.58%), 19% for myalgia (95% CI 16–23; $I^2$ 95%), 12% for headache (95% CI 9–15; $I^2$ 93.12%), 10% for back pain (95% CI 1–23; $I^2$ 80.20%), 10% for dizziness (95% CI 3–19%; $I^2$ 86.74%), 3% for acute cerebrovascular disease (95% CI 1–5%; $I^2$ 0%), and 2% for impaired consciousness (95% CI 1–2%; $I^2$ 0%). Figure 2 shows the forest plots for the prevalence of acute cerebrovascular disease, impaired consciousness, back pain, dizziness, headache, myalgia, smell impairment, and taste impairment.

The visual symmetry of the funnel plots suggests that there was no publication bias for headache, dizziness, and myalgia. These results were also confirmed by Egger’s test, which revealed statistically insignificant $p$-values. See Figure 3 for the funnel plots.

**DISCUSSION**

The results showed that the prevalence of neurological and musculoskeletal manifestations of COVID-19 was 35% for smell impairment, 33% for taste impairment, 19% for myalgia, 12% for headache, 10% for back pain, 3% for acute cerebrovascular disease, and 2% for impaired consciousness. In addition, the majority of the studies have excellent methodological quality, which is an indication of the validity and reliability of the studies (77). Thus, it is important that clinicians consider these symptoms during diagnosis of the disease and management of the patients to help prevent the spread of the disease and the development of any complications. For instance, acute cerebrovascular disease can manifest as symptoms such as stroke, seizure, and headache, which can result in long-term disability that may require rehabilitation for a very long time (78–80). Similarly, symptoms such as muscle weakness, myalgia, vision impairment, and arthralgia can interfere with patients’ ability to carry out activities of daily living (ADL). When people are able to carry out ADL, they tend to have better quality of life (11, 12).

In addition, two of the most important factors about COVID-19 are that it is highly contagious and most of the people infected may not present with any notable symptoms such as fever and cough (56). This means that the presence of some previously unnoticed symptoms such as muscle weakness, visual impairment, and arthralgia may not raise any suspicion of the disease. As such, many unnoticed cases could infect many others and increase the spread of the disease. Delineating the whole spectrum of the symptoms patients with COVID-19 present with can help with prompt diagnosis, isolation, and treatment of cases.

One important finding in this study is that there are more neurological symptoms than musculoskeletal symptoms in patients with COVID-19. This may not be surprising, as the virus is believed to be neurotrophic, and the patients may...
TABLE 1 | Details and characteristics of the included studies.

| References | Country   | Study design | Number of patients (overall) | Number of patients (critical) | Number of patients (non-critical) | Number of male patients | Mean/median age (years) | Headache | Dizziness | Impaired consciousness | Acute cerebrovascular disease | Ataxia | Delirium | Tissue Impairment | Small bowel perforation | Vision impairment | Nerve pain | Myalgia | Back pain | Muscle weakness | Skeletal muscle injury | Arthralgia | Facial muscle pain | Illness onset | Neurological symptoms |
|------------|-----------|--------------|------------------------------|------------------------------|---------------------------------|------------------------------|------------------------|----------------|-------------|------------------------|-------------------------------|--------|----------|----------------|------------------------|----------------|-------------|--------|----------|----------------|------------------------|-------------|----------------|-----------|-------------------|
| Feng et al.  | China     | Cohort       | 476                          | 124                          | 352                             | 271                           | 53 (40–60)            | NA         | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | 4 (2–7) | 47/440                          |
| Leï et al. (21)  | China     | Cross-sectional | 199                         | 24                          | 53                              | 77                            | 49.35 (40–60)          | NA         | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | NA         | NA                              |
| Zhang et al. (22)  | China     | Cross-sectional | 120                          | 30                          | 90                              | 43                            | 45.4 (40–60)           | NA         | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | NA         | NA                              |
| Han et al. (23)  | China     | Cross-sectional | 108                          | NA                          | NA                              | 38                            | 45 (40–60)             | NA         | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | NA         | NA                              |
| Qian et al. (25)  | China     | Cross-sectional | 91                           | NA                          | NA                              | 37                            | 50 (IQR, 36.5 to 57.0)  | 7           | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | NA         | NA                              |
| Chen et al. (26)  | China     | Cross-sectional | 99                           | NA                          | NA                              | 67                            | 55.5 (13–1)            | 8           | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | NA         | NA                              |
| Jin et al. (27)  | China     | Cross-sectional | 651                          | NA                          | NA                              | 331                           | 45.62 (40–60)          | 67          | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | NA         | NA                              |
| Zhang et al. (28)  | China     | Cross-sectional | 645                          | NA                          | NA                              | 328                           | 40.78 (40–60)          | 67          | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | NA         | NA                              |
| Lü et al. (29)  | China     | Cross-sectional | 10                           | 4                           | 6                               | 3                             | 54 (27–64)             | NA          | 2          | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | 1–3 (1)  | NA                              |
| Morishita et al. (30)  | Japan     | Case report    | 1                           | NA                          | NA                              | 1                             | 24                    | NA          | 1          | 1 NA                   | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | NA         | NA                              |
| Du et al. (31)  | China     | Cross-sectional | 109                          | 51                          | 58                              | 74                            | 70.7 (40–60)           | 8           | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | NA         | NA                              |
| Zhang et al. (32)  | China     | Case series    | 5                           | NA                          | NA                              | 4                             | 45                    | NA          | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | NA         | NA                              |
| Gane et al. (33)  | UK        | Case report    | 1                           | NA                          | NA                              | 1                             | 48                    | NA          | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | NA         | NA                              |
| Mao et al. (34)  | China     | Case series    | 214                          | 58.2                        | 58.2                            | 87                            | 131                   | 28          | 36         | 16                     | 6 1 1 12 11 3 NA          | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | NA         | NA                              |
| Han et al. (35)  | China     | Cross-sectional | 17                           | NA                          | NA                              | 6                             | 40                    | NA          | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | NA         | NA                              |
| Léchène et al. (36)  | Multi-center/Europe | Cross-sectional | 417                          | NA                          | NA                              | 154                           | 36.9 ± 14.4           | 188         | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | 133 (130) | NA                              |
| Jin and Tong (37)  | China     | Case report    | 1                           | NA                          | 1                               | 1                             | 60                    | NA          | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | NA         | NA                              |
| Barrasa et al. (38)  | Spain     | Cross-sectional | 48                           | 48                          | 0                               | 27                            | 63.2 (40–60)          | NA          | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | 2 NA       | NA                              |
| Eliezer et al. (39)  | France    | Case report    | 1                           | 0                            | 1                               | 0                             | 40                    | NA          | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | NA         | NA                              |
| Zhao et al. (10)  | China     | Case report    | 1                           | 0                            | 1                               | 0                             | 61                    | NA          | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | NA         | NA                              |
| Kim et al. (40)  | USA       | Case report    | 1                           | NA                          | 1                               | 1                             | 42                    | NA          | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | NA         | NA                              |
| Lian et al. (41)  | China     | Retrospective study | 788                          | 78                          | 710                             | 407                           | 54.72 (40–60)         | 75          | NA         | NA                     | NA                           | NA     | NA       | NA             | NA                     | NA            | NA         | NA     | NA       | NA             | NA                     | NA         | NA         | 91 NA     | NA                              |
| References       | Country     | Study design       | Number of patients (overall) | Number of patients (critical) | Number of patients (non-critical) | Number of male patients | Mean/median age (years) | Headache | Dizziness | Impaired consciousness | Acute cerebrovascular disease | Aphasie | Seizure | Tactile impairment | Small impairment | Vision impairment | New pain | Myalgia | Back pain | Muscle weakness | Skelatal muscle injury | Amnesia | Facial muscle pain | Illness onset | Neurological symptoms |
|-----------------|-------------|--------------------|-----------------------------|------------------------------|-------------------------------|-------------------------------|------------------------|---------------------|-----------|-----------|----------------------|-----------------------------|----------|---------|-------------------|-----------------|-------------------|---------|--------|-----------|------------------|----------------------|---------|-----------------|------------------|----------------------|
| Shi et al.      | China       | Cohort study       | 416                         | NA                           | NA                            | 205                           | 64 (21–95)            | 9                   | NA        | NA        | NA                   | NA                          | NA       | NA      | NA                | NA              | NA                | NA      | NA     | NA        | NA               | NA                  | NA      | NA              | NA               | NA                   |
| Yan et al.      | USA         | Cross sectional    | 59                           | NA                           | NA                            | 29                            | 18–79                  | 25                  | NA        | NA        | NA                   | NA                          | NA       | NA      | NA                | NA              | NA                | NA      | NA     | NA        | NA               | NA                  | NA      | NA              | NA               | NA                   |
| Yang et al.     | China       | Case report        | 4                            | NA                           | NA                            | 1                             | NA                     | 2                   | NA        | NA        | NA                   | NA                          | NA       | NA      | NA                | NA              | NA                | NA      | NA     | NA        | NA               | NA                  | NA      | NA              | NA               | NA                   |
| Li et al.       | China       | Retrospective study| 10                          | NA                           | NA                            | 2                             | 34–87                  | 1                   | NA        | NA        | NA                   | NA                          | NA       | NA      | NA                | NA              | NA                | NA      | NA     | NA        | NA               | NA                  | NA      | NA              | NA               | NA                   |
| Wu et al.       | China       | Retrospective study| 80                          | NA                           | NA                            | 42                            | 44 [11]                 | 8                   | NA        | NA        | NA                   | NA                          | NA       | NA      | NA                | NA              | NA                | NA      | NA     | NA        | NA               | NA                  | NA      | NA              | NA               | NA                   |
| Lei et al.      | China       | Retrospective study| 14                          | NA                           | NA                            | 8                             | 12–83                  | 2                   | NA        | NA        | NA                   | NA                          | NA       | NA      | NA                | NA              | NA                | NA      | NA     | NA        | NA               | NA                  | NA      | NA              | NA               | NA                   |
| Xu et al.       | China       | Retrospective study| 50                          | 37                           | 13                            | 29                            | 43.9 ± 16.8            | 5                   | NA        | NA        | NA                   | NA                          | NA       | NA      | NA                | NA              | NA                | NA      | NA     | NA        | NA               | NA                  | NA      | NA              | NA               | NA                   |
| Li et al.       | China       | Retrospective study| 25                          | 16                           | 9                             | 12                            | 48                     | NA                  | NA        | NA        | NA                   | NA                          | NA       | NA      | NA                | NA              | NA                | NA      | NA     | NA        | NA               | NA                  | NA      | NA              | NA               | NA                   |
| Yang et al.     | China       | Retrospective multi-center cohort study | 149 | NA | 81 | 45.1 ± 13.35 | 13 | NA | NA | NA | NA | NA | NA | NA | 5 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
TABLE 1 | Continued

| Reference | Country | Study design | Number of patients (overall) | Number of patients (non-critical) | Number of patients (critical) | Mean/median age (years) | Headache | Dizziness | Impaired consciousness | Acute cerebrovascular disease | Anxiety | Sleep impairment | Vision impairment | New pain | Myalgia | Back pain | Muscle weakness | Facial muscle pain | Illness onset | Neurological symptoms |
|-----------|---------|--------------|-------------------------------|----------------------------------|-------------------------------|---------------------------|-----------------|-----------|----------------------|-----------------------------|---------|------------------|-------------------|----------|---------|-----------|-----------------|------------------|-------------|-------------------|
| Kim et al. (63) | South Korea | Cohort study | 28 | 28 | 0 | 42.6 | 7 | NA | NA | NA | NA | NA | NA | NA | NA | 7 | 7 | NA | NA | NA | NA | NA | NA |
| Cheng et al. (64) | China | Cohort | 11 | NA | NA | 8 | 50.36 | NA | NA | NA | NA | NA | NA | NA | NA | NA | 3 | NA | NA | NA | NA | NA | NA | NA |
| Xu et al. (65) | China | Cross sectional | 51 | NA | NA | 25 | 42 | NA | NA | NA | NA | NA | NA | NA | NA | NA | 8 | NA | NA | NA | NA | NA | NA | NA |
| Cao et al. (66) | China | Cross sectional | 102 | NA | NA | 53 | 45 | NA | NA | NA | NA | NA | NA | NA | NA | NA | 35 | NA | NA | NA | NA | NA | NA |
| Wan et al. (67) | China | Cohort | 135 | 56 | 40 | 95 | 49 | 34 | NA | NA | NA | NA | NA | NA | NA | NA | 44 | NA | NA | NA | NA | NA | NA |
| Wang et al. (68) | China | Cross sectional | 69 | 14 | 55 | 32 | 42 | 10 | NA | NA | NA | NA | NA | NA | NA | NA | 21 | NA | NA | NA | NA | NA | NA |
| Du et al. (69) | China | Cross sectional | 85 | 85 | 0 | 62 | 65.8 | 4 | NA | NA | NA | NA | NA | NA | NA | NA | 14 | NA | NA | NA | NA | NA | NA |
| Huang et al. (70) | China | Cross sectional | 41 | 13 | 28 | 30 | 49.0 | 3 | NA | NA | NA | NA | NA | NA | NA | NA | 18 | NA | NA | NA | NA | NA | NA |
| Xu et al. (71) | China | Cross sectional | 62 | NA | NA | 35 | 41 | 21 | NA | NA | NA | NA | NA | NA | NA | NA | 32 | NA | NA | NA | NA | NA | NA |
| Dongyan et al. (72) | China | Case report | 1 | 0 | 1 | 1 | 35 | NA | NA | NA | NA | NA | NA | NA | NA | NA | 1 | NA | NA | NA | NA | NA | NA |
| Wang et al. (73) | China | Cross sectional | 339 | NA | NA | 166 | 69 | 12 | NA | NA | NA | NA | NA | NA | AN | NA | 16 | NA | NA | NA | NA | NA | NA |
| Cai et al. (74) | China | Cross sectional | 298 | 58 | 240 | 145 | 47.5 | NA | NA | NA | NA | NA | NA | NA | NA | NA | 12 | NA | NA | NA | NA | NA | NA |
| Tape et al. (75) | USA | Case report | 1 | NA | NA | 0 | 79 | NA | NA | 1 | NA | NA | NA | NA | NA | NA | NA | 1 | NA | NA | NA | NA | NA | NA |
| Bhatnagar et al. (76) | USA | Cross sectional | 24 | 24 | 0 | 15 | 64 | NA | NA | NA | NA | NA | NA | NA | NA | NA | 107 | NA | NA | NA | NA | NA | NA |
| Goyal et al. (77) | USA | Case series | 393 | NA | NA | 238 | 62.2 | NA | NA | NA | NA | NA | NA | NA | NA | NA | 4 | NA | NA | NA | NA | NA | NA |
| Toscano et al. (78) | Italy | Case report | 5 | 3 | 2 | NA | NA | NA | NA | NA | NA | 1 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
TABLE 2 | Levels of evidence and methodological quality of the included studies.

| References | Design | Level of evidence | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | Total score |
|------------|--------|-------------------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feng et al. (20) | Cohort | III-2 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | NA | Yes | Yes | Yes | NA | Yes | 9/9 |
| Lei et al. (21) | Cross-sectional | III-2 | Yes | Yes | Yes | No | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | No | Yes | 9/11 |
| Zhang et al. (22) | Cross-sectional | III-2 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | NA | Yes | 9/9 |
| Han et al. (23) | Cross-sectional | III-2 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | Yes | NA | Yes | 8/9 |
| Qian et al. (25) | Cross-sectional | III-2 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | NA | Yes | 9/9 |
| Chen et al. (26) | Cross-sectional | III-2 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | Yes | NA | Yes | 7/9 |
| Jin et al. (27) | Cross-sectional | III-2 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | Yes | NA | Yes | 7/9 |
| Zhang et al. (28) | Cross-sectional | III-2 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |
| Lon et al. (29) | Cross-sectional | III-2 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | Yes | Yes | Yes | 8/9 |
| Moriguchi et al. (30) | Case report | IV | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | Yes | Yes | Yes | Yes | 8/9 |
| Du et al. (31) | Cross-sectional | III-3 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | Yes | Yes | Yes | Yes | 8/9 |
| Zhang et al. (32) | Case series | IV | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | Yes | Yes | Yes | Yes | 8/9 |
| Gane et al. (33) | Case report | IV | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | Yes | Yes | Yes | Yes | 8/9 |
| Mao et al. (34) | Case series | IV | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |
| Han et al. (35) | Cross-sectional | III-2 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |
| Lechien et al. (36) | Cross-sectional | III-2 | Yes | Yes | Yes | No | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |
| Jin and Tong (37) | Case report | IV | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |
| Barrasa et al. (38) | Cross-sectional | III-2 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |
| Eliezer et al. (39) | Case report | IV | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | Yes | Yes | Yes | Yes | 7/9 |
| Zhao et al. (40) | Case report | IV | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | Yes | Yes | Yes | Yes | 8/9 |
| Kim et al. (41) | Case report | IV | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | Yes | Yes | Yes | Yes | 8/9 |
| Lian et al. (42) | Retrospective study | III-3 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |
| Shi et al. (43) | Cohort | III-3 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |
| Yan et al. (44) | Cross-sectional | III-1 | Yes | Yes | Yes | No | NA | NA | No | No | NA | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | 8/12 |
| Yang et al. (45) | Case report | IV | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | Yes | Yes | Yes | Yes | 8/9 |
| Mi et al. (46) | Retrospective cohort study | III-3 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | NA | Yes | Yes | Yes | Yes | Yes | 8/9 |
| Wu et al. (47) | Retrospective study | III-3 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |
| Lei et al. (48) | Retrospective study | III-2 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |
| Xu et al. (49) | Retrospective study | III-1 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |
| Li et al. (50) | Retrospective study | III-2 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |
| Yang et al. (51) | Retrospective cohort study | III-2 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |
| Chen et al. (52) | Retrospective study | III-3 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |
| Liang et al. (53) | Retrospective cohort study | III-2 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |
| Chen et al. (54) | Retrospective study | III-2 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |
| Hu et al. (55) | Retrospective study | III-2 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |
| Chu et al. (56) | Retrospective study | III-2 | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |
| Wang et al. (57) | Case series | IV | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | Yes | Yes | Yes | Yes | 9/9 |

(Continued)
### TABLE 2 | Continued

| References          | Design                             | Level of evidence | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | Total score |
|---------------------|------------------------------------|-------------------|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|-------------|
| Zheng et al. (57)   | Retrospective study               | III-2             | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | NA | Yes | 9/9 |
| Guan et al. (58)    | Cohort                            | III-2             | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | NA | Yes | 8/9 |
| Wu et al. (59)      | Retrospective multi-center descriptive | III-2             | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | NA | Yes | 8/9 |
| Wang et al. (60)    | Descriptive                       | III-2             | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | NA | Yes | 9/9 |
| Wang et al. (61)    | Retrospective study               | III-2             | Yes | No  | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | NA | Yes | 7/9 |
| Ye et al. (24)      | Cohort                            | III-2             | Yes | No  | No  | NA | NA | NA | Yes | Yes | NA | NA | No | No | Yes | NA | Yes | 5/9 |
| Yang et al. (62)    | Retrospective study               | III-3             | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | NA | Yes | 9/9 |
| Kim et al. (63)     | Cohort study                       | III-2             | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | No | Yes | NA | Yes | 7/9 |
| Cheng et al. (64)   | Cohort                            | III-1             | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | NA | Yes | 9/9 |
| Xu et al. (65)      | Cross-sectional                   | III-2             | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | NA | Yes | 9/9 |
| Cao et al. (66)     | Cohort                            | III-2             | Yes | Yes | Yes | No | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | NA | Yes | 9/10 |
| Wan et al. (67)     | Cohort                            | III-2             | Yes | Yes | Yes | No | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | NA | Yes | 9/10 |
| Wang et al. (68)    | Cross-sectional                   | III-2             | Yes | Yes | Yes | No | NA | NA | Yes | Yes | NA | NA | Yes | Yes | No | Yes | 9/11 |
| Du et al. (69)      | Cross-sectional                   | III-2             | Yes | Yes | Yes | No | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | No | Yes | 9/9 |
| Huang et al. (4)    | Cross-sectional                   | III-2             | Yes | Yes | Yes | No | NA | NA | Yes | Yes | NA | NA | Yes | Yes | Yes | No | Yes | 9/10 |
| Xu et al. (73)      | Cross-sectional                   | III-2             | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | NA | Yes | 8/9 |
| Dongyan et al. (71) | Case report                       | IV                | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | NA | Yes | 8/9 |
| Wang et al. (72)    | Cross-sectional                   | III-2             | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | NA | Yes | 8/9 |
| Cai et al. (73)     | Cross-sectional                   | III-2             | Yes | Yes | Yes | No | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | No | Yes | 8/11 |
| Tape et al. (74)    | Case report                       | IV                | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | NA | Yes | 8/9 |
| Bhatraju et al. (75)| Cross sectional                   | IV                | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | NA | Yes | 8/9 |
| Goyal et al. (76)   | Retrospective case series         | IV                | Yes | Yes | Yes | NA | NA | NA | Yes | Yes | NA | NA | No | Yes | Yes | NA | Yes | 8/9 |
| Toscano et al. (9)  | Case report                       | IV                | Yes | No  | Yes | NA | NA | NA | Yes | Yes | NA | Yes | No | NA | Yes | NA | Yes | 7/9 |
therefore present with neurological symptoms or complications, especially in the long term (81, 82). Similarly, it is also possible that the patients will present with more musculoskeletal symptoms and complications in the long-term due to prolonged immobilization (83, 84). It is also worth noting that many of the symptoms in patients with COVID-19 are non-specific and cannot be highlighted as support for the early diagnosis of the disease. For instance, symptoms such as headache and impaired consciousness may be related to the respiratory failure. However, based on the reviewed studies reporting on the situations of the patients, the majority of the participants were not in critical condition. Therefore, it cannot be said with certainty that these non-specific symptoms are the result of respiratory failure.

Nevertheless, several factors may be the likely causes of the neurological and musculoskeletal features of COVID-19. Firstly, the virus may gain access to, for example, the central nervous system via the bloodstream and infect endothelial cells or leukocytes or through retrograde neuronal routes by infecting the peripheral nerves (85). Secondly, the virus causes pneumonia, which may result in systemic hypoxia, which will...
eventually damage the brain and other nerve cells (86). The processes through which the damage occurs include peripheral vasodilatation, hypercapnia, hypoxia, and anaerobic metabolism, which ultimately result in neuronal swelling and brain edema (87). Neural swelling and brain edema can raise intracranial pressure and result in impaired consciousness and seizure or can irritate the trigeminal nerve and cause headache (88, 89).

In addition, cytokine storms characterized by increased levels of inflammatory cytokines and activities of T lymphocytes, macrophages, and endothelial cells can also cause neuronal damage. In particular, the release of interleukin-6 causes vascular leakage and activation of complement and coagulation cascades (90). Consequently, it was noted that patients with the severe disease (COVID-19) tend to have higher levels of D-dimer, which is a marker of a hypercoagulable state and endogenous fibrinolysis (34, 91). These may be the factors that cause acute cerebrovascular disease in patients with COVID-19. Similarly, the elevated level of serum interleukin-6 during cytokine storms could be the cause of myalgia (92). The cytokine storm may also be the cause of the arthralgia presented by the patients. This is because interleukin-6 is a pro-inflammatory substance (93), and viral infections are also known to cause arthralgia (94). Thus, it is possible that arthralgia, which is joint pain, is associated with myalgia in patients with COVID-19.

Although we excluded studies in children because they generally present only with mild fever and cough (14), we recommend that they should be kept under close observation, since damage to the developing nervous system can be devastating. According to the World Health Organization (WHO), recent findings on symptoms in children testing positive for COVID-19 have shown unexplained inflammatory syndrome, mostly in several European and North American countries (95). However, due to the uncertainties of the definitions of symptoms associated with COVID-19 in children, it is important that more evidence is allowed to emerge before their presenting symptoms are categorized into definite neurological and/or musculoskeletal symptoms (95).

This review has multiple strengths, such as the estimation of prevalence for both neurological and musculoskeletal manifestations, the inclusion of a large number of studies (n = 60) with considerable sample size (n = 11,069), the assessment of methodological quality and the level of evidence, and the use of proportional meta-analyses for the quantitative data. In addition, even though two systematic reviews on the neurological features of COVID-19 have been published previously (96, 97), this review seems to be the only one reporting symptoms such low-back and facial pain. Similarly, the study also has some limitations. One of the limitations is that the reviewed studies could not account for whether or not the neurological and musculoskeletal symptoms of COVID-19 are due to the comorbidities and/or the medicines the patients use for the comorbidities. This is because a number of comorbidities are reported in the studies, and possibly the comorbidities or the drugs the patients take may be responsible for one or more of these neurological or musculoskeletal symptoms. Other limitations are related to the search process, where gray literature databases were not searched and non-English language studies were not included. However, the lists of references of all included studies were screened to include all relevant studies and reduce the risk of publication bias. Furthermore, the heterogeneity between studies was high in most of the meta-analysis results. This may impact negatively on the certainty of the findings.

CONCLUSIONS

Patients with COVID-19 present with many different symptoms, including those that affect the neurological and musculoskeletal systems. Therefore, delineating the whole spectrum of symptoms of the disease can help with early diagnosis, prevention of the spread of the disease, and its treatment. In addition, it will help with the prevention of complications that may arise in the long term.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

AUTHOR CONTRIBUTIONS

AA conceived and designed (initially) the study and wrote up the results (with inputs from BK) and the discussion. SC, BK, NU, AB, EA, MAb, and MAI provided inputs to improve the design of the study. In particular, SC and BK modified the search strategy and the data extraction form. BK searched the literature. AA and SC selected the studies for eligibility. AA, NU, and MAb extracted the study data. AB, AA, and NU did the assessment of the methodological quality of the included studies. AA did the qualitative synthesis, and BK did the meta-analysis. AA and EA wrote up the introduction. MAI wrote up the methodology, which was modified by AA. SC, BK, EA, and MAI critically reviewed the manuscript. All authors contributed to the article and approved the submitted version.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fneur.2020.00687/full#supplementary-material

REFERENCES

1. Xu T, Chen G, Zhu Z, Cui M, Chen C, Dai H, et al. Clinical features and dynamics of viral load in imported and non-imported patients with COVID-19. Int J Infect Dis. (2020) 64:68-71. doi: 10.1016/j.ijid.2020.03.022
2. Zhiwen Hu, Zhongliang Y, Qi L, Yongfeng H. Infodemiological study on COVID-19 epidemic and COVID-19 infodemic. (2020). doi: 10.21203/rs.3.rs-18591/v1
3. Sun P, Lu X, Xu C, Sun W, Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. (2020) 92:548-51. doi: 10.1002/jmv.25722
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. (2020) 395:497–506. doi: 10.1016/S0140-6736(20)30183-5

5. Castronova V, Rabovsky J, Tucker JH, Miles PR. The alveolar type II epithelial cell: a multifunctional pneumocyte. *Toxicol Appl Pharm.* (1988) 93:472–85. doi: 10.1016/0041-008X(88)90051-8

6. Adhikari SP, Meng S, Wu Y-J, Mao Y-P, Ye R-X, Wang Q-Z, et al. Neurological and Musculoskeletal Features of COVID-19. *(Am J Respir Crit Care Med)*. (2020) 201:1380–88. doi: 10.1164/rccm.202002-0445OC

7. Hartman-Maeir A, Soroker N, Ring H, Avni N, Katz N. Activities, participation and satisfaction one-year post stroke. *Disabil Rehabil*. (2007) 29:559–66. doi: 10.1080/09638280600992996

8. Huang YH, Wu CY, Hsieh YW, Lin KC. Predictors of change in quality of life after distributed constraint-induced therapy in patients with chronic stroke. *Neurorehabil Neural Repair*. (2010) 24:559–66. doi: 10.1177/1545968309358074

9. Liberati A, Altman DG, Tetzlaff J, Mulrow C. The PRISMA statement for reporting systematic reviews and meta-analyses of studies evaluate health care interventions: explanation and elaboration. *PLoS Med.* (2009) 6:e1000100. doi: 10.1371/journal.pmed.1000100

10. Hartman-Maeir A, Soroker N, Ring H, Avni N, Katz N. Activities, participation and satisfaction one-year post stroke. *Disabil Rehabil*. (2007) 29:559–66. doi: 10.1080/09638280600992996

11. Law HK, Cheung CY, Ng HY, Dison Y, Chan YO, Luk WM, et al. Chemokine upregulation in SARS coronavirus infected human monocyte derived dendritic cells. *Bloom.* (2005) 106:2366–7. doi: 10.1182/blood-2004-10-4166

12. Szakmany M, Hammad F, Fedorowicz Z, Elmagarmid A, Rayyan: a web and mobile application for systematic reviews. *Syst Rev*. (2016) 5:210. doi: 10.1186/s13643-016-0384-4

13. Law HK, Cheung CY, Ng HY, Sia SF, Chan YO, Luk WM, et al. Chemokine upregulation in SARS coronavirus infected human monocyte derived dendritic cells. *Blood.* (2005) 106:2366–76. doi: 10.1182/blood-2004-10-4166

14. Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Horoi M, et al. Isolated sudden onset anosmia in patients with COVID-19. *Clin Infect Dis.* (2020) 9:707–13. doi: 10.1093/cid/ciaa1751.2020.1744483

15. Ouzzani M, Hammad F, Fedorowicz Z, Elmagarmid A, Rayyan: a web and mobile application for systematic reviews. *Syst Rev*. (2016) 5:210. doi: 10.1186/s13643-016-0384-4

16. Law HK, Cheung CY, Ng HY, Sia SF, Chan YO, Luk WM, et al. Chemokine upregulation in SARS coronavirus infected human monocyte derived dendritic cells. *Bloom.* (2005) 106:2366–76. doi: 10.1182/blood-2004-10-4166

17. Council-NHaMR. NHMRC levels of evidence and grades for recommendations for guideline developers. Canberra, ACT: National Health and Medical Research Council (2009).

18. Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. *J Epidemiol Community Health*. (2013) 67:974–8. doi: 10.1136/jech-2013-203104

19. Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of Interventions*. Cochrane Book Series. Chichester: Wiley-Blackwell Publications (2011).

20. Fong Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. COVID-19 with different severity: A multi-center study of clinical features. *Am J Respir Crit Care Med*. (2020) 201:1380–88. doi: 10.1164/rccm.202002-0445OC

21. Lei Z, Cao H, Yusheng Jie Y, Huang Z, Guo X, Chen J, et al. A cross-sectional comparison of epidemiological and clinical features of patients with coronavirus disease (COVID-19) in Wuhan and outside Wuhan, China. *Travel Med Infec Dis*. (2020) 101664. doi: 10.1016/j.tmaid.2020.101664

22. Zhang R, Ouyang H, Fu L, Wang S, Han J, Huang K, et al. CT features of SARS-CoV-2 pneumonia according to clinical presentation: a retrospective analysis of 120 consecutive patients from Wuhan city. *Eur Radiol*. (2020) 10.1007/s00330-020-06854-1

23. Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D. Early clinical and CT manifestations of Coronavirus Disease 2019 (COVID-19) pneumonia. *Am J Roentgenol*. (2020) 1–6. doi: 10.2214/AJR.20.22961

24. Ye G, Pan Z, Pan Y, Deng Q, Chen L, Li J, et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. *J Infect*. (2020) 80:e14–17. doi: 10.1016/j.jinf.2020.03.001
coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19. *J Korean Med. Sci.* (2020) 35:e142. doi: 10.3346/jkms.2020.35.e142
44. Cheng Z, Lu Y, Cao Q, Qin L, Pan Z, Yan F, et al. Clinical features and chest CT manifestations of coronavirus disease 2019 (COVID-19) in a single-center study in Shanghai, China. *Am J Roentgenol.* (2020) 1–6. doi: 10.2214/AJR.20.22599
45. Xie F, Wu Z, An W, Wang X, Wu X, Wang J, et al. Clinical and chest CT features. *Invest Radiol.* (2020) 55:257–61. doi: 10.1097/RLI.0000000000000670
46. Lei P, Huang Z, Liu G, Peng P, Song W, Mao J, et al. Clinical and computed tomographic (CT) images characteristics in the patients with COVID-19 infection: what should radiologist need to know? *J X-ray Sci. Tech.* (2020) 1–13. doi: 10.3233/XST-200670
47. Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical characteristics of 99 case of 2019 novel coronavirus pneumonia in Wuhan, China. *J Respir Med.* (2020) 80:125–31. doi: 10.1080/01406736.2020.1740912
48. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics and outcomes of 138 hospitalized patients with 2019 novel coronavirus – infected pneumonia in Wuhan – China. *J Am Med Assoc.* (2020) 323:1061–9. doi: 10.1001/jama.2020.1585
49. Zheng F, Tang W, Li H, Huang LX, Xie YL, Zhou ZG. Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. *Eur Rev Med Pharmacol Sci.* (2020) 24:3404–10. doi: 10.26355/currev_202003_20711
50. Gao W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical characteristics of coronavirus disease 2019 in China. *N Eng J Med.* (2020) 382:1708–20. doi: 10.1056/NEJMoa200232
51. Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. Clinical characteristics of imported cases of coronavirus disease 2019 (COVID-19) in Jiangsu province: a multicenter descriptive study. *Clin Infect Dis.* (2020) ciaa199. doi: 10.1093/cid/ciaa199
52. Wang X, Fang J, Zhu Y, Chen I, Ding F, Zhou R, et al. Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang hospital. *Clin Microbiol Infect.* (2020). doi: 10.1016/j.cmi.2020.03.032. [Epub ahead of print]
53. Liu K, Fang YY, Deng Y, Liu Y, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei province. *Clin Med J.* (2020) 133:1025–31. doi: 10.1097/CMJ.0000000000001744
54. Yang Z, Le Y, Ming H, Minqiang H, Xuedong S, Weidong Z, et al. Case report on early diagnosis of COVID-19. *Disaster Med Pub Health Preparedness.* (2020) 1–4. doi: 10.1017/dmph.2020.66
55. Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi JP, et al. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19. *J Korean Med. Sci.* (2020) 35:e142. doi: 10.3346/jkms.2020.35.e142
in the quality and quantity of muscle and is related to muscle strength and function. *J Crit Care.* (2015) 30:1151.e9-14. doi: 10.1016/j.jcrc.2015.05.024
84. Puthucheary ZA, Rawal J, McPhail M, Connolly B, Ratnayake G, Chan P, et al. Acute skeletal muscle wasting in critical illness. *JAMA.* (2015) 310:1591–600. doi: 10.1001/jama.2013.278481
85. Desforges M, Le Coupunec A, Dubepau P, Bourguin A, Lajoie L, Dube M, et al. Human Coronavirus and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? *Viruses.* (2019) 12:14. doi: 10.3390/v12010014
86. Ahmad I, Rathore FA. Neurological manifestations and complications of COVID-19: a literature review. *J Clin Neurosci.* (2020) doi: 10.1016/j.jocn.2020.05.017
87. Tu H, Tu S, Gao S, Shao A, Sheng J. The epidemiological and clinical features of COVID-19 and lessons from this global infectious public health event. *J Infect.* (2020) doi: 10.1016/j.jinf.2020.04.011. [Epub ahead of print].
88. Uchida D, Fujimoto A, Yamazoe T, Yamamoto T, Enok H. Seizure frequency can be reduced by changing intracranial pressure: A case report in drug-resistant epilepsy. *Epilepsy Behav Case Rep.* (2018) 10:14–17. doi: 10.1016/j.ebcr.2017.12.005
89. Ogunlaja OI, Cowan R. Subarachnoid hemorrhage and headache. *Curr Pain Headache Rep.* (2019) 23:44. doi: 10.1007/s11916-019-0785-x
90. Mehta P, McAuley DE, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet.* (2020) 395:1033–4. doi: 10.1016/S0140-6736(20)30628-0
91. Li Y, Wang M, Zhou Y, Chang J, Xian Y, Mao L, et al. Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. *SSRN Electr J.* (2020) doi: 10.2139/ssrn.3550025. [Epub ahead of print].
92. Nakamura K, Saito K, Hara Y, Aoyagi T, Kitakawa K, Abe Y, et al. Severe epidemic myalgia with an elevated level of serum interleukin-6 caused by human parechovirus type 3: a case report and brief review of the literature. *BMC Infect Dis.* (2018) 18:381. doi: 10.1186/s12879-018-3284-5
93. Tanaka T, Narazaki M, Kishimoto T. IL-6 in Inflammation, immunity, and disease. *Cold Spring Harb Perspect Biol.* (2014) 6:a016295. doi: 10.1101/cshperspect.a016295
94. World Health Organization Report. *Multisystem Inflammatory Syndrome in Children and Adolescents With COVID-19: Scientific Brief.* (2020) reference number: WHO/2019-CoV/Sci /2020.1.
95. Pinzon RT, Wijaya VO, Buana RB, Jody AA, Nunsio PN. Neurologic characteristics in Coronavirus Disease 2019 (COVID-19): a systematic review and meta-analysis. *Front Neurol.* (2020) 19:105921. doi: 10.3389/fneur.2020.00565
96. Tsai S-T, Lu M-K, San S, Tsai C-H. The neurologic manifestations of Coronavirus Disease 2019 pandemic: a systemic review. *Front Neurol.* (2020) 11:498. doi: 10.3389/fneur.2020.00498

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

*Copyright © 2020 Abdullahi, Candan, Abba, Bello, Abibehri, Anamefuna Victor, Umar and Kundakci. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.*